Formations et évènements
ESMO Congress 2022 Congress
09-13 septembre 2022
Virtuel
L'édition 2021 aura lieu du 16 au 21 septembre 2021 avec 3 abstracts IFCT sélectionnés :
Proffered Paper session (LBA)
Nivolumab (nivo) ± Ipilimumab (ipi) in pre-treated Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (GCO-001 NIPINEC)
Thomas Walter
Voir le communiqué sur l'étude GCO-001 NIPINEC
Proffered Paper session
An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: characterisation of PORT efficacy in Lung ART (IFCT-0503, UK NCRI, SAKK)
Cécile Le Pechoux
Mini oral session
Pathological response is an independent factor of overall survival and disease-free survival after neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase 2 trial.
Marie Wislez
Pathological response is an independent factor of overall survival and disease-free survival after neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase 2 trial.
Marie Wislez